NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) Friday reported positive Phase 3 ICONIC-TOTAL data for Icotrokinra, a once-daily oral peptide that selectively inhibits the IL-23 receptor.
The company noted that among adults and adolescents with at least moderate plaque psoriasis in high-impact areas, 57 percent of Icotrokinra-treated patients achieved clear or almost clear skin at Week 16 versus 6 percent on placebo.
Icotrokinra also delivered notable clearance in challenging regions: 66 percent achieved clear or almost clear scalp, and 77 percent reached minimal genital involvement. In a smaller hand/foot cohort, 42 percent responded versus 26 percent with placebo.
The treatment was well-tolerated, with similar adverse event rates to placebo and no new safety signals, underscoring its potential as a convenient, effective oral option for moderate-to-severe plaque psoriasis.
JNJ is currently trading at $155.43 down $0.24 or 0.15 percent on the New York Stock Exchange.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
